1. Short title This Act may be cited as the Consumer Vaccine Safety and Protection Act of 2023 . 2. Disclosure of non-exempt data required for certain biological products and other drugs Section 319F–3 of the Public Health Service Act ( 42 U.S.C. 247d–6b ) is amended by adding at the end the following: (j) Disclosure of non-Exempt data required (1) Covered products In this subsection, the term covered product means a covered countermeasure that— (A) is a biological product or other drug; and (B) is authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act on or after the date of enactment of the Consumer Vaccine Safety and Protection Act of 2023 , irrespective of whether the biological product or drug later receives approval or licensure under section 505 of the Federal Food, Drug, and Cosmetic Act or section 351 of this Act. (2) Disclosure by sponsors (A) In general Subject to subparagraph (C), the sponsor of a covered product shall disclose to the public, in an easily accessible location on the website of the sponsor of the covered product— (i) in the case of a biological product, all data and information available for public disclosure under section 601.51(e) of title 21, Code of Federal Regulations (or successor regulations); and (ii) in the case of another drug, all data and information available for public disclosure under section 314.430 of title 21, Code of Federal Regulations (or successor regulations). (B) Timing The sponsor of a covered product shall, with respect to any data or information required to be disclosed by subparagraph (A), make the disclosure not later than 10 days after the later of— (i) the date on which the Food and Drug Administration authorizes the emergency use of the covered product under section 564 of the Federal Food, Drug, and Cosmetic Act